Povidone-Iodine Oral Rinse Study

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Mouth rinse

Registration Number: NCT05239598

Lead Sponsor: University of Pennsylvania

Brief Summary: This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing SARS-CoV-2 load in COVID 19+ adult individuals. Phase II is designed as an open label trial, and all subjects will receive the active mouthwash.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 40

Inclusion Criteria

Able and willing to provide informed consent prior to initiation of study procedures.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male or female, aged 18 years and older.
Clinical diagnosis of COVID-19 infection confirmed with a positive point of care test.
Confirmed diagnosis within 5 days of baseline visit (within 5 days of COVID-19 test) and at least one clinical COVID-19 symptom [*Signs and symptoms of COVID-19 present at illness onset vary, but over the course of the disease, most people will experience the following: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste of smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea.]
Presents with a minimum of six natural teeth.
Ability to rinse/gargle with study products.
Not using mouth rinse/gargling solutions at the time of enrollment.
Not taking antimicrobial medications (antibacterial, antiviral, antibiotics, including hydroxychloroquine) at time of enrollment.
Ability to participate in the study and come to site during Phase I of the study for collection of swabs and saliva.
Willing to use an acceptable method of birth control throughout duration of the study. Acceptable methods include hormonal contraceptives, barrier methods, abstinence, or other effective methods approved by the PI.
If continuing to Phase II of the trial, ability to continue using study products for 1 week (+ 3 days). (Participants do not have to agree to participate in Phase II in order to participate in Phase I.)
If continuing to Phase II of the trial, agree to receive text messages/phone calls containing questionnaires regarding compliance and use of study product, and reminders, able to complete virtual follow-up study visit for collection of outcomes data.

Exclusion Criteria

Individuals receiving antiviral medications
Pregnant or breastfeeding women (for premenopausal women of childbearing potential, pregnancy status to be confirmed through a urine pregnancy test during the study visit)
Inability to comply with study protocol
Having an allergy to any of the study mouthwash ingredients
Having any thyroid condition.
Presents with a current suspicious oral lesion at the examiner's discretion, and/or currently undergoing radiation therapy for head or neck cancer, and/or has received radiation therapy to the head or neck (including radioactive iodine therapy).

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Mouth rinse	Subjects will be asked to rinse/gargle one time with 10 mL of placebo mouth rinse for 30 seconds.
Povidone-iodine 0.5% antiseptic mouth rinse	Mouth rinse	Subjects will be asked to rinse/gargle one time with 10 mL of Povidone-iodine 0.5% antiseptic mouth rinse for 30 seconds.

Primary Outcome Measures

Name	Time	Method
[PCR Saliva] Percent Change From Baseline Ct Viral Targets	60 minutes after intervention	The primary endpoint is the percentage reduction of SARS-Co-V-2 load in saliva at 60 minutes (post-intervention) compared to baseline between the PVP-I mouthwash versus the placebo mouthwash. For this outcome, Cycle Threshold is a proxy for SARS-Co-V-2 load. A positive percent change from baseline Cycle Threshold indicates a decrease from baseline SAR-Co-V2. \[Quick SARS-CoV-2 rRT-PCR Kit (Zymo Research, Cat. No. R3011)\].

Secondary Outcome Measures

Name	Time	Method
[PCR Saliva] Percent Change From Baseline Cycle Threshold at 5 and 30 Minutes Post Intervention	5 and 30 minutes post-intervention	The secondary endpoints are the percentage reduction of SARS-Co-V-2 load in saliva at 5 and 30 minutes (post-intervention) compared to baseline between the PVP-I mouthwash versus the placebo mouthwash. For this outcome, Cycle Threshold is a proxy for SARS-Co-V-2 load. A positive percent change from baseline Cycle Threshold indicated a decrease from baseline SARS-Co-V-2.